Drug intelligence / Profile preview

STW 5-II

Development stage
Phase 4
Lead developer
Steigerwald Arzneimittelwerk
Modality
Small Molecules
Administration
Oral
01

Overview

STW 5-II is a multi-target herbal phytomedicine developed for the treatment of functional gastrointestinal disorders, specifically functional dyspepsia (FD) and irritable bowel syndrome (IBS). It is a refined six-herb formulation derived from the original nine-herb product STW 5 (Iberogast). The preparation consists of hydroethanolic extracts of bitter candytuft (*Iberis amara*), peppermint leaf (*Mentha x piperita*), chamomile flower (*Matricaria recutita*), licorice root (*Glycyrrhiza glabra*), caraway fruit (*Carum carvi*), and melissa leaf (*Melissa officinalis*). STW 5-II exerts its therapeutic effects through a multi-target approach: it modulates gastrointestinal motility in a region-specific manner (relaxing the proximal stomach while increasing distal contractility), reduces visceral hypersensitivity by desensitizing intestinal afferents, exhibits anti-inflammatory properties, and protects gut barrier integrity by stabilizing tight junction proteins. It has recently been introduced into various European markets for the management of disorders of gut-brain interaction (DGBIs).

Brand names
Iberogast AdvanceIberogast-N
Other names
Six-herb combination IberogastIberogast NSTW 5-II herbal preparationSTW5-II herbal preparationSTW-5-II herbal preparation
02

Targets

NF-κBCRHR2 (Corticotropin-releasing hormone receptor 2)STAT1 (Signal transducer and activator of transcription protein 1)CRHR1 (Corticotropin-releasing factor receptor 1)NOS2 (Nitric Oxide Synthase 2)TLR4 (Toll-like receptor 4)Bradykinin B2 receptor

Beyond the preview

Go deeper on STW 5-II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STW 5-II.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call